A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
A. Dimitrios Colevas(Cancer Institute (WIA)), Douglas Adkins(Washington University in St. Louis), Venessa Chin(Garvan Institute of Medical Research), Jared Odegard(Gilead Sciences (United States)), Bruno Fang, José Dinis(Instituto Português de Oncologia Francisco Gentil), Diogo Alpuim Costa(Hospital do Desterro), Lance U’Ren(Incyte (United States)), Erika Pirtle(Gilead Sciences (United States)), Yiran Zhang(Gilead Sciences (United States)), Minh Phan(University of Oklahoma Health Sciences Center), Kelly K. Curtis(Gilead Sciences (United States)), John Park(California Baptist University)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k